Recently, Zhang et al. reported that the combination of piperlongumine and oxaliplatin significantly inhibited TrxR1 activity in gastric cancer cells, leading to increased ROS production and oxidative stress, suggesting that piperlongumine synergistically potentiates the antitumour effect of oxaliplatin both in vitro and in vivo [161]. Here, TXNRD1 is linked to gastric cancer.